Sleep Disturbances in Parkinson's Disease: A Scoping Review

Carolina Vieira Naia; Giovana de Souza Faria; Flávio de Lima Filho; Artur Consulo Dionísio; Luana Passos Oliveira; Marissa Prudente Pinheiro Guizardi; Marina Feitosa de Castro Aguiar; Júlio César Claudino dos Santos; Luana Stangherlin

doi:10.52600/2965-0968.bjcmr.2025.3.1.bjcmr22

Health Review

Vol. 3 No. 1 (2025): January/December - 2025

Sleep Disturbances in Parkinson's Disease: A Scoping Review

Carolina Vieira Naia^▸^▾
Giovana de Souza Faria^▸^▾
Flávio de Lima Filho^▸^▾
Artur Consulo Dionísio^▸^▾
Luana Passos Oliveira^▸^▾
Marissa Prudente Pinheiro Guizardi^▸^▾
Marina Feitosa de Castro Aguiar^▸^▾
Júlio César Claudino dos Santos^▸^▾
Luana Stangherlin^▸^▾

DOI: https://doi.org/10.52600/2965-0968.bjcmr.2025.3.1.bjcmr22
Submitted: October 21, 2024
Published: 2024-11-21

Abstract

Neurodegenerative diseases (ND), such as Parkinson's disease (PD) and Alzheimer's disease (AD), are characterized by progressive neuronal loss and degeneration, leading to both motor and non-motor symptoms, including sleep disturbances. Sleep disorders are highly prevalent in PD, affecting between 60% and 98% of patients. These include insomnia, excessive daytime sleepiness (EDS), sleep-disordered breathing, obstructive sleep apnea (OSA), restless legs syndrome (RLS), circadian rhythm disorders, and REM sleep behavior disorder (RBD). This article provides a comprehensive literature review on the pathophysiology, diagnosis, and management of sleep disorders in patients with PD. We highlight the significant impact these disturbances have on quality of life and emphasize the importance of regular screening and individualized treatment plans. Additionally, we discuss the challenges posed by non-motor symptoms in PD, particularly those related to sleep, as they often do not respond well to traditional dopaminergic therapies. Future research should aim to enhance diagnostic techniques and develop more targeted, patient-centered interventions to improve the management of sleep disorders in PD.

References

Zuzuárregui JRP, During EH. Sleep issues in Parkinson's disease and their management. Neurotherapeutics. 2020;17(4):1480–94. https://doi.org/10.1007/s13311-020-00938-y.
Hunt J, Coulson EJ, Rajnarayanan R, Oster H, Videnovic A, Rawashdeh O. Sleep and circadian rhythms in Parkinson's disease and preclinical models. Mol Neurodegener. 2022;17(1):2. https://doi.org/10.1186/s13024-021-00504-w.
Barone P, Antonini A, Colosimo C, Marconi R, Morgante L, Avarello TP, et al. The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. Mov Disord. 2009;24(11):1641–9. https://doi.org/10.1002/mds.22643.
Ylikoski A, Martikainen K, Sieminski M, Partinen M. Parkinson's disease and insomnia. Neurol Sci. 2015;36(11):2003–10. https://doi.org/10.1007/s10072-015-2288-9.
Erro R, Santangelo G, Picillo M, Vitale C, Amboni M, Longo K, et al. Link between non-motor symptoms and cognitive dysfunctions in de novo, drug-naive PD patients. J Neurol. 2012;259(9):1808–13. https://doi.org/10.1007/s00415-011-6407-0.
Rosa-Grilo M, Qamar MA, Taddei RN, Pagonabarraga J, Kulisevsky J, Sauerbier A, et al. Rotigotine transdermal patch and sleep in Parkinson's disease: where are we now? NPJ Parkinsons Dis. 2017;3:28. https://doi.org/10.1038/s41531-017-0030-4.
Tandberg E, Larsen JP, Karlsen K. A community-based study of sleep disorders in patients with Parkinson's disease. Mov Disord. 1998;13(6):895–9. https://doi.org/10.1002/mds.870130606.
Trenkwalder C, Kohnen R, Högl B, Metta V, Sixel-Döring F, Frauscher B, et al. Parkinson's disease sleep scale--validation of the revised version PDSS-2. Mov Disord. 2011;26(4):644–52. https://doi.org/10.1002/mds.23476.
Marinus J, Visser M, van Hilten JJ, Lammers GJ, Stiggelbout AM. Assessment of sleep and sleepiness in Parkinson disease. Sleep. 2003;26(8):1049–54. https://doi.org/10.1093/sleep/26.8.1049.
Stavitsky K, Saurman JL, McNamara P, Cronin-Golomb A. Sleep in Parkinson's disease: a comparison of actigraphy and subjective measures. Parkinsonism Relat Disord. 2010;16(4):280–3. https://doi.org/10.1016/j.parkreldis.2010.02.001.
Suzuki K, Miyamoto M, Miyamoto T, Okuma Y, Hattori N, Kamei S, et al. Correlation between depressive symptoms and nocturnal disturbances in Japanese patients with Parkinson's disease. Parkinsonism Relat Disord. 2009;15(1):15–9. https://doi.org/10.1016/j.parkreldis.2008.02.002.
Gros P, Videnovic A. Sleep and circadian rhythm disorders in Parkinson's disease. Curr Sleep Med Rep. 2017;3(3):222–34. https://doi.org/10.1007/s40675-017-0079-y.
Yoo SW, Kim JS, Oh YS, Ryu DW, Lee KS. Excessive daytime sleepiness and its impact on quality of life in de novo Parkinson's disease. Neurol Sci. 2019;40(6):1151–6. https://doi.org/10.1007/s10072-019-03785-8.
Liguori C, Mercuri NB, Albanese M, Olivola E, Stefani A, Pierantozzi M. Daytime sleepiness may be an independent symptom unrelated to sleep quality in Parkinson's disease. J Neurol. 2019;266(3):636–41. https://doi.org/10.1007/s00415-018-09179-8.
Frucht S, Rogers JD, Greene PE, Gordon MF, Fahn S. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology. 1999;52(9):1908–10. https://doi.org/10.1212/wnl.52.9.1908.
Högl B, Seppi K, Brandauer E, Glatzl S, Frauscher B, Niedermüller U, et al. Increased daytime sleepiness in Parkinson's disease: a questionnaire survey. Mov Disord. 2003;18(3):319–23. https://doi.org/10.1002/mds.10365.
Monaca C, Duhamel A, Jacquesson JM, Ozsancak C, Destée A, et al. Vigilance troubles in Parkinson's disease: a subjective and objective polysomnographic study. Sleep Med. 2006;7(5):448–53. https://doi.org/10.1016/j.sleep.2005.12.002.
Amara AW, Chahine LM, Caspell-Garcia C, Long JD, Coffey C, Högl B, et al. Longitudinal assessment of excessive daytime sleepiness in early Parkinson's disease. J Neurol Neurosurg Psychiatry. 2017;88(8):653–62. https://doi.org/10.1136/jnnp-2016-315023.
O'Suilleabhain PE, Dewey RB Jr. Contributions of dopaminergic drugs and disease severity to daytime sleepiness in Parkinson disease. Arch Neurol. 2002;59(6):986–9. https://doi.org/10.1001/archneur.59.6.986.
Yeung EYH, Cavanna AE. Sleep attacks in patients with Parkinson's disease on dopaminergic medications: A systematic review. Mov Disord Clin Pract. 2014;1(4):307–16. https://doi.org/10.1002/mdc3.12063.
Valko PO, Hauser S, Sommerauer M, Werth E, Baumann CR. Observations on sleep-disordered breathing in idiopathic Parkinson's disease. PLoS One. 2014;9(6). https://doi.org/10.1371/journal.pone.0100828.
Kaminska M, Lafontaine AL, Kimoff RJ. The interaction between obstructive sleep apnea and Parkinson's disease: Possible mechanisms and implications for cognitive function. Parkinsons Dis. 2015;2015:849472. https://doi.org/10.1155/2015/849472.
Neikrug AB, Liu L, Avanzino JA, Maglione JE, Natarajan L, Bradley L, et al. Continuous positive airway pressure improves sleep and daytime sleepiness in patients with Parkinson disease and sleep apnea. Sleep. 2014;37(1):177–85. https://doi.org/10.5665/sleep.3332.
Kylstra WA, Aaronson JA, Hofman WF, Schmand BA. Neuropsychological functioning after CPAP treatment in obstructive sleep apnea: A meta-analysis. Sleep Med Rev. 2013;17(5):341–7. https://doi.org/10.1016/j.smrv.2012.09.002.
Lévy P, Kohler M, McNicholas WT, Barbé F, McEvoy RD, Somers VK, et al. Obstructive sleep apnoea syndrome. Nat Rev Dis Primers. 2015;1:15015. https://doi.org/10.1038/nrdp.2015.15.
Trotti LM, Bliwise DL. No increased risk of obstructive sleep apnea in Parkinson's disease. Mov Disord. 2010;25(13):2246–9. https://doi.org/10.1002/mds.23231.
Cochen De Cock V, Abouda M, Leu S, Oudiette D, Roze E, Vidailhet M, et al. Is obstructive sleep apnea a problem in Parkinson's disease? Sleep Med. 2010;11(3):247–52. https://doi.org/10.1016/j.sleep.2009.05.008.
Bahia CMCS, Pereira JS, Lopes AJ. Laryngopharyngeal motor dysfunction and obstructive sleep apnea in Parkinson's disease. Sleep Breath. 2019;23(2):543–50. https://doi.org/10.1007/s11325-018-1729-0.
Tsai CC, Wu MN, Liou LM, Chang YP. Levodopa reverses stridor and prevents subsequent endotracheal intubation in Par-kinson disease patients with bilateral vocal cord palsy: A case report. Medicine (Baltimore). 2016;95(50). https://doi.org/10.1097/MD.0000000000005559.
Mery VP, Gros P, Lafontaine AL, Robinson A, Benedetti A, Kimoff RJ, et al. Reduced cognitive function in patients with Parkinson disease and obstructive sleep apnea. Neurology. 2017;88(12):1120–8. https://doi.org/10.1212/WNL.0000000000003738.
Huang JY, Zhang JR, Shen Y, Zhang HJ, Cao YL, Mao CJ, et al. Effect of rapid eye movement sleep behavior disorder on obstructive sleep apnea severity and cognition of Parkinson's disease patients. Chin Med J (Engl). 2018;131(8):899–906. https://doi.org/10.4103/0366-6999.229888.
Arnulf I, Konofal E, Merino-Andreu M, Houeto JL, Mesnage V, Lacomblez L, et al. Parkinson's disease and sleepiness: An integral part of PD. Neurology. 2002;58(7):1019–24. https://doi.org/10.1212/wnl.58.7.1019.
Hardie RJ, Efthimiou J, Stern GM. Respiration and sleep in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1986;49(11):1326. https://doi.org/10.1136/jnnp.49.11.1326.
Hovestadt A, Bogaard JM, Meerwaldt JD, van der Meché FG, Stigt J. Pulmonary function in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1989;52(3):329–33. https://doi.org/10.1136/jnnp.52.3.329.
Darien IL. The diagnostic criteria of the American Academy of Sleep Medicine. The International Classification of Sleep Disorders. 3rd ed. Darien (IL): American Academy of Sleep Medicine; 2014.
Bonuccelli U, Del Dotto P, Lucetti C, Petrozzi L, Bernardini S, Gambaccini G, et al. Diurnal motor variations to repeated doses of levodopa in Parkinson's disease. Clin Neuropharmacol. 2000;23(1):28–33. https://doi.org/10.1097/00002826-200001000-00006.
Bolitho SJ, Naismith SL, Rajaratnam SM, Grunstein RR, Hodges JR, Terpening Z, et al. Disturbances in melatonin secretion and circadian sleep-wake regulation in Parkinson disease. Sleep Med. 2014;15(3):342–7. https://doi.org/10.1016/j.sleep.2013.10.016.
Golombek DA, Rosenstein RE. Physiology of circadian entrainment. Physiol Rev. 2010;90(3):1063–102. https://doi.org/10.1152/physrev.00009.2009.
Breen DP, Vuono R, Nawarathna U, Fisher K, Shneerson JM, Reddy AB, et al. Sleep and circadian rhythm regulation in early Parkinson disease. JAMA Neurol. 2014;71(5):589–95. https://doi.org/10.1001/jamaneurol.2014.65.
Paus S, Schmitz-Hübsch T, Wüllner U, Vogel A, Klockgether T, Abele M. Bright light therapy in Parkinson's disease: A pilot study. Mov Disord. 2007;22(10):1495–8. https://doi.org/10.1002/mds.21542.
Videnovic A, Klerman EB, Wang W, Marconi A, Kuhta T, Zee PC. Timed light therapy for sleep and daytime sleepiness associated with Parkinson disease: A randomized clinical trial. JAMA Neurol. 2017;74(4):411–8. https://doi.org/10.1001/jamaneurol.2016.5192.
Willis GL, Turner EJ. Primary and secondary features of Parkinson's disease improve with strategic exposure to bright light: A case series study. Chronobiol Int. 2007;24(3):521–37. https://doi.org/10.1080/07420520701420717.
Zhong G, Bolitho S, Grunstein R, Naismith SL, Lewis SJ. The relationship between thermoregulation and REM sleep behaviour disorder in Parkinson's disease. PLoS One. 2013;8(8). https://doi.org/10.1371/journal.pone.0072661.
Bordet R, Devos D, Brique S, Touitou Y, Guieu JD, Libersa C, et al. Study of circadian melatonin secretion pattern at different stages of Parkinson's disease. Clin Neuropharmacol. 2003;26(2):65–72. https://doi.org/10.1097/00002826-200303000-00005.
Cai Y, Liu S, Sothern RB, Xu S, Chan P. Expression of clock genes Per1 and Bmal1 in total leukocytes in health and Parkinson's disease. Eur J Neurol. 2010;17(4):550–4. https://doi.org/10.1111/j.1468-1331.2009.02848.x.
Mantovani S, Smith SS, Gordon R, O'Sullivan JD. An overview of sleep and circadian dysfunction in Parkinson's disease. J Sleep Res. 2018;27(3). https://doi.org/10.1111/jsr.12673.
Garcia-Borreguero D, Serrano C, Larrosa O, Granizo JJ. Circadian effects of dopaminergic treatment in restless legs syndrome. Sleep Med. 2004;5(4):413–20. https://doi.org/10.1016/j.sleep.2004.01.007.
Verbaan D, van Rooden SM, van Hilten JJ, Rijsman RM. Prevalence and clinical profile of restless legs syndrome in Parkinson's disease. Mov Disord. 2010;25(13):2142–7. https://doi.org/10.1002/mds.23241.
Yang X, Liu B, Shen H, Li S, Zhao Q, An R, et al. Prevalence of restless legs syndrome in Parkinson's disease: A systematic review and meta-analysis of observational studies. Sleep Med. 2018;43:40–6. https://doi.org/10.1016/j.sleep.2017.11.1146.
Szatmari S Jr, Bereczki D, Fornadi K, Kalantar-Zadeh K, Kovesdy CP, Molnar MZ. Association of restless legs syndrome with incident Parkinson's disease. Sleep. 2017;40(2). https://doi.org/10.1093/sleep/zsw065.
Lee JE, Shin HW, Kim KS, Sohn YH. Factors contributing to the development of restless legs syndrome in patients with Parkinson disease. Mov Disord. 2009;24(4):579–82. https://doi.org/10.1002/mds.22410.
Angelini M, Negrotti A, Marchesi E, Bonavina G, Calzetti S. A study of the prevalence of restless legs syndrome in previously untreated Parkinson's disease patients: Absence of co-morbid association. J Neurol Sci. 2011;310(1-2):286–8. https://doi.org/10.1016/j.jns.2011.08.012.
Moccia M, Erro R, Picillo M, Santangelo G, Spina E, Allocca R, et al. A four-year longitudinal study on restless legs syndrome in Parkinson disease. Sleep. 2016;39(2):405–12. https://doi.org/10.5665/sleep.5452.
Ferini-Strambi L, Carli G, Casoni F, Galbiati A. Restless legs syndrome and Parkinson disease: A causal relationship between the two disorders? Front Neurol. 2018;9:551. https://doi.org/10.3389/fneur.2018.00551.
Alonso-Navarro H, García-Martín E, Agúndez JAG, Jiménez-Jiménez FJ. Association between restless legs syndrome and other movement disorders. Neurology. 2019;92(20):948–64. https://doi.org/10.1212/WNL.0000000000007500.
Allen RP, Picchietti DL, Garcia-Borreguero D, Ondo WG, Walters AS, Winkelman JW, et al. Restless legs syndro-me/Willis-Ekbom disease diagnostic criteria: Updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria—history, rationale, description, and significance. Sleep Med. 2014;15(8):860–73. https://doi.org/10.1016/j.sleep.2014.03.025.
Silber MH, Becker PM, Earley C, Garcia-Borreguero D, Ondo WG, Medical Advisory Board of the Willis-Ekbom Disease Foundation. Willis-Ekbom Disease Foundation revised consensus statement on the management of restless legs syndrome. Mayo Clin Proc. 2013;88(9):977–86. https://doi.org/10.1016/j.mayocp.2013.06.016.
Ondo WG. Common comorbidities and differential diagnosis of restless legs syndrome. J Clin Psychiatry. 2014;75(3). https://doi.org/10.4088/JCP.12074nr2c.
Garcia-Borreguero D, Kohnen R, Silber MH, Winkelman JW, Earley CJ, Högl B, et al. The long-term treatment of restless legs syndrome/Willis-Ekbom disease: Evidence-based guidelines and clinical consensus best practice guidance: A report from the International Restless Legs Syndrome Study Group. Sleep Med. 2013;14(7):675–84. https://doi.org/10.1016/j.sleep.2013.05.016.
Cochen De Cock V. Therapies for restless legs in Parkinson's disease. Curr Treat Options Neurol. 2019;21(11):56. https://doi.org/10.1007/s11940-019-0596-8.
Maria B, Sophia S, Michalis M, Charalampos L, Andreas P, John ME, et al. Sleep breathing disorders in patients with idiopathic Parkinson's disease. Respir Med. 2003;97(10):1151–7. https://doi.org/10.1016/s0954-6111(03)00188-4.
Schroeder LA, Rufra O, Sauvageot N, Fays F, Pieri V, Diederich NJ. Reduced rapid eye movement density in Parkinson disease: A polysomnography-based case-control study. Sleep. 2016;39(12):2133–9. https://doi.org/10.5665/sleep.6312.
Diederich NJ, Rufra O, Pieri V, Hipp G, Vaillant M. Lack of polysomnographic Non-REM sleep changes in early Parkinson's disease. Mov Disord. 2013;28(10):1443–6. https://doi.org/10.1002/mds.25520.
Wetter TC, Brunner H, Högl B, Yassouridis A, Trenkwalder C, Friess E. Increased alpha activity in REM sleep in de novo patients with Parkinson's disease. Mov Disord. 2001;16(5):928–33. https://doi.org/10.1002/mds.1163.
Margis R, Schönwald SV, Carvalho DZ, Gerhardt GJ, Rieder CR. NREM sleep alpha and sigma activity in Parkinson's disease: Evidence for conflicting electrophysiological activity? Clin Neurophysiol. 2015;126(5):951–8. https://doi.org/10.1016/j.clinph. 2014.07.034.
Ohayon MM, Schenck CH. Violent behavior during sleep: Prevalence, comorbidity and consequences. Sleep Med. 2010;11(9):941–6. https://doi.org/10.1016/j.sleep.2010.02.016.
Högl B, Stefani A, Videnovic A. Idiopathic REM sleep behaviour disorder and neurodegeneration—An update. Nat Rev Neurol. 2018;14(1):40–55. https://doi.org/10.1038/nrneurol.2017.157.
Iranzo A, Tolosa E, Gelpi E, Molinuevo JL, Valldeoriola F, Serradell M, et al. Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: An observational cohort study. Lancet Neurol. 2013;12(5):443–53. https://doi.org/10.1016/S1474-4422(13)70056-5.
Boeve BF, Silber MH, Ferman TJ, Lin SC, Benarroch EE, Schmeichel AM, et al. Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder. Sleep Med. 2013;14(8):754–62. https://doi.org/10.1016/j.sleep.2012.10.015.
Mahlknecht P, Seppi K, Poewe W. The concept of prodromal Parkinson's disease. J Parkinsons Dis. 2015;5(4):681–97. https://doi.org/10.3233/JPD-150685.
Pagano G, De Micco R, Yousaf T, Wilson H, Chandra A, Politis M. REM behavior disorder predicts motor progression and cognitive decline in Parkinson disease. Neurology. 2018;91(10)–e905. https://doi.org/10.1212/WNL.0000000000006134.
Oertel WH, Henrich MT, Janzen A, Geibl FF. The locus coeruleus: Another vulnerability target in Parkinson's disease. Mov Disord. 2019;34(10):1423–9. https://doi.org/10.1002/mds.27785.
Weinshenker D. Long road to ruin: Noradrenergic dysfunction in neurodegenerative disease. Trends Neurosci. 2018;41(4):211–23. https://doi.org/10.1016/j.tins.2018.01.010.
Gjerstad MD, Tysnes OB, Larsen JP. Increased risk of leg motor restlessness but not RLS in early Parkinson disease. Neurology. 2011;77(22):1941–6. https://doi.org/10.1212/WNL.0b013e31823a0cc8.
Pierantozzi M, Placidi F, Liguori C, Albanese M, Imbriani P, Marciani MG, et al. Rotigotine may improve sleep architecture in Parkinson's disease: A double-blind, randomized, placebo-controlled polysomnographic study. Sleep Med. 2016;21:140–4. https://doi.org/10.1016/j.sleep.2016.01.016.
Seppi K, Ray Chaudhuri K, Coelho M, Fox SH, Katzenschlager R, Perez Lloret S, et al. Update on treatments for nonmotor symptoms of Parkinson's disease—an evidence-based medicine review. Mov Disord. 2019;34(2):180–98. https://doi.org/10.1002/mds.27602.
Postuma RB, Anang J, Pelletier A, Joseph L, Moscovich M, Grimes D, et al. Caffeine as symptomatic treatment for Parkinson disease (Café-PD): A randomized trial. Neurology. 2017;89(17):1795–803. https://doi.org/10.1212/WNL.0000000000004568.
Winkelman JW, Armstrong MJ, Allen RP, Chaudhuri KR, Ondo W, Trenkwalder C, et al. Practice guideline summary: Tre-atment of restless legs syndrome in adults: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2016;87(24):2585–93. https://doi.org/10.1212/WNL.00000000 00003388.
Allen RP, Picchietti DL, Garcia-Borreguero D, Ondo WG, Walters AS, Winkelman JW, et al. Restless legs syndro-me/Willis-Ekbom disease diagnostic criteria: Updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria—history, rationale, description, and significance. Sleep Med. 2014;15(8):860–73. https://doi.org/10.1016/j.sleep.2014.03.025.
Howell MJ, Arneson PA, Schenck CH. A novel therapy for REM sleep behavior disorder (RBD). J Clin Sleep Med. 2011;7(6):639–44A. https://doi.org/10.5664/jcsm.1470.
Wang Y, Yang Y, Wu H, Lan D, Chen Y, Zhao Z. Effects of Rotigotine on REM Sleep Behavior Disorder in Parkinson Disease. J Clin Sleep Med. 2016;12(10):1403–9. https://doi.org/10.5664/jcsm.6200.
Di Giacopo R, Fasano A, Quaranta D, Della Marca G, Bove F, Bentivoglio AR. Rivastigmine as alternative treatment for refractory REM behavior disorder in Parkinson's disease. Mov Disord. 2012;27(4):559–61. https://doi.org/10.1002/mds.24909.
Schenck CH, Högl B, Videnovic A, eds. Rapid-eye-movement sleep behavior disorder. Cham: Springer; 2019.
Stefani A, Högl B. Sleep in Parkinson’s disease. Neuropsychopharmacol Rep. 2020;40(5):362–70. https://doi.org/10.1002/ npr2.12152.
Pierantozzi M, Placidi F, Liguori C, Albanese M, Imbriani P, Marciani MG, et al. Rotigotine may improve sleep architecture in Parkinson's disease: A double-blind, randomized, placebo-controlled polysomnographic study. Sleep Med. 2016;21:140–4. https://doi.org/10.1016/j.sleep.2016.01.016.
Seppi K, Ray Chaudhuri K, Coelho M, Fox SH, Katzenschlager R, Perez Lloret S, et al. Update on treatments for nonmotor symptoms of Parkinson's disease—an evidence-based medicine review. Mov Disord. 2019;34(2):180–98. https://doi.org/ 10.1002/mds.27602.
Neikrug AB, Liu L, Avanzino JA, Maglione JE, Natarajan L, Bradley L, et al. Continuous positive airway pressure improves sleep and daytime sleepiness in patients with Parkinson disease and sleep apnea. Sleep. 2014;37(1):177–85. https://doi.org/10.5665/sleep.3332.
Schäfer D. Schlafbezogene Atmungsstörungen bei Parkinsonsyndromen: Häufigkeit, Art und Behandlungsansätze: Sleep-related breathing disorders in Parkinsonism: Frequency, nature, and therapeutical approaches. Somnologie. 2001;5(3):103–14.
Bollu PC, Sahota P. Sleep and Parkinson Disease. Mo Med. 2017;114(5):381–6.
Videnovic A, Klerman EB, Wang W, Marconi A, Kuhta T, Zee PC. Timed light therapy for sleep and daytime sleepiness associated with Parkinson disease: A randomized clinical trial. JAMA Neurol. 2017;74(4):411–8. https://doi.org/10.1001/jamaneurol.2016.5192.
Wang Y, Yang Y, Wu H, Lan D, Chen Y, Zhao Z. Effects of Rotigotine on REM sleep behavior disorder in Parkinson disease. J Clin Sleep Med. 2016;12(10):1403–9. https://doi.org/10.5664/jcsm.6200.
Di Giacopo R, Fasano A, Quaranta D, Della Marca G, Bove F, Bentivoglio AR. Rivastigmine as alternative treatment for refractory REM behavior disorder in Parkinson's disease. Mov Disord. 2012;27(4):559–61. https://doi.org/10.1002/mds.24909.
Howell MJ, Arneson PA, Schenck CH. A novel therapy for REM sleep behavior disorder (RBD). J Clin Sleep Med. 2011;7(6):639–44A. https://doi.org/10.5664/jcsm.1470.
Allen RP, Picchietti DL, Garcia-Borreguero D, Ondo WG, Walters AS, Winkelman JW, et al. Restless legs syndro-me/Willis-Ekbom disease diagnostic criteria: Updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria—history, rationale, description, and significance. Sleep Med. 2014;15(8):860–73. https://doi.org/10.1016/j.sleep.2014.03.025.
Silber MH, Becker PM, Earley C, Garcia-Borreguero D, Ondo WG, Medical Advisory Board of the Willis-Ekbom Disease Foundation. Willis-Ekbom Disease Foundation revised consensus statement on the management of restless legs syndrome. Mayo Clin Proc. 2013;88(9):977–86. https://doi.org/10.1016/j.mayocp.2013.06.016.
Ondo WG. Common comorbidities and differential diagnosis of restless legs syndrome. J Clin Psychiatry. 2014;75(3). https://doi.org/10.4088/JCP.12074nr2c.
Garcia-Borreguero D, Kohnen R, Silber MH, Winkelman JW, Earley CJ, Högl B, et al. The long-term treatment of restless legs syndrome/Willis-Ekbom disease: Evidence-based guidelines and clinical consensus best practice guidance: A report from the International Restless Legs Syndrome Study Group. Sleep Med. 2013;14(7):675–84. https://doi.org/10.1016/j.sleep.2013.05.016.
Cochen De Cock V. Therapies for restless legs in Parkinson's disease. Curr Treat Options Neurol. 2019;21(11):56. https://doi.org/10.1007/s11940-019-0596-8.
Schenck CH, Högl B, Videnovic A, editors. Rapid-eye-movement sleep behavior disorder. Cham: Springer; 2019.
Wang Y, Yang Y, Wu H, Lan D, Chen Y, Zhao Z. Effects of Rotigotine on REM sleep behavior disorder in Parkinson disease. J Clin Sleep Med. 2016;12(10):1403–9. https://doi.org/10.5664/jcsm.6200.
Di Giacopo R, Fasano A, Quaranta D, Della Marca G, Bove F, Bentivoglio AR. Rivastigmine as alternative treatment for refractory REM behavior disorder in Parkinson's disease. Mov Disord. 2012;27(4):559–61. https://doi.org/10.1002/mds.24909.
Stefani A, Högl B, Videnovic A. Non-motor features of Parkinson's disease and sleep disorders: Practical guidelines for assessment and management. Mov Disord Clin Pract. 2020;7(3):250–66. https://doi.org/10.1002/mdc3.12899.
Pierantozzi M, Placidi F, Liguori C, Albanese M, Imbriani P, Marciani MG, et al. Rotigotine may improve sleep architecture in Parkinson's disease: A double-blind, randomized, placebo-controlled polysomnographic study. Sleep Med. 2016;21:140–4. https://doi.org/10.1016/j.sleep.2016.01.016.
Seppi K, Ray Chaudhuri K, Coelho M, Fox SH, Katzenschlager R, Perez Lloret S, et al. Update on treatments for nonmotor symptoms of Parkinson's disease—An evidence-based medicine review. Mov Disord. 2019;34(2):180–98. https://doi.org/10.1002/mds.27602.
Postuma RB, Anang J, Pelletier A, Joseph L, Moscovich M, Grimes D, et al. Caffeine as symptomatic treatment for Parkinson disease (Café-PD): A randomized trial. Neurology. 2017;89(17):1795–803. https://doi.org/10.1212/WNL.0000000000004568.
Neikrug AB, Liu L, Avanzino JA, Maglione JE, Natarajan L, Bradley L, et al. Continuous positive airway pressure improves sleep and daytime sleepiness in patients with Parkinson disease and sleep apnea. Sleep. 2014;37(1):177–85. https://doi.org/10.5665/sleep.3332.
Schäfer D. Schlafbezogene Atmungsstörungen bei Parkinsonsyndromen: Häufigkeit, Art und Behandlungsansätze: Sleep-related breathing disorders in Parkinsonism: Frequency, nature, and therapeutical approaches. Somnologie. 2001;5(3):103–14. https://doi.org/10.1007/s11818-001-0015-5.
Winkelman JW, Armstrong MJ, Allen RP, Chaudhuri KR, Ondo W, Trenkwalder C, et al. Practice guideline summary: Tre-atment of restless legs syndrome in adults: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2016;87(24):2585–93. https://doi.org/10.1212/WNL.00000000 00003388.
Videnovic A, Klerman EB, Wang W, Marconi A, Kuhta T, Zee PC. Timed light therapy for sleep and daytime sleepiness associated with Parkinson disease: A randomized clinical trial. JAMA Neurol. 2017;74(4):411–8. https://doi.org/10.1001/jamaneurol.2016.5192.
Paus S, Schmitz-Hübsch T, Wüllner U, Vogel A, Klockgether T, Abele M. Bright light therapy in Parkinson's disease: A pilot study. Mov Disord. 2007;22(10):1495–8. https://doi.org/10.1002/mds.21542.
Howell MJ, Arneson PA, Schenck CH. A novel therapy for REM sleep behavior disorder (RBD). J Clin Sleep Med. 2011;7(6):639–44A. https://doi.org/10.5664/jcsm.1470.
Wang Y, Yang Y, Wu H, Lan D, Chen Y, Zhao Z. Effects of Rotigotine on REM sleep behavior disorder in Parkinson disease. J Clin Sleep Med. 2016;12(10):1403–9. https://doi.org/10.5664/jcsm.6200.
Di Giacopo R, Fasano A, Quaranta D, Della Marca G, Bove F, Bentivoglio AR. Rivastigmine as alternative treatment for refractory REM behavior disorder in Parkinson's disease. Mov Disord. 2012;27(4):559–61. https://doi.org/10.1002/mds.24909.

Most read articles by the same author(s)

Lia de Oliveira Jereissati, Luiz Aldir da Silva, Tiago Antoniol, Vitor Olímpio Coimbra, Alexandre Almeida da Silva, Amanda Rebouças Bezerra de Menezes, Gabriel Felipe Gomes, Stéfani Lara Galvão, Roger Wilson Gonçalves de Oliveira, Nayla Lima dos Santos, Pamella Mendes Martiniano da Silva Cardoso, Luciano Barroso de Albuquerque Filho, Camilla Costa Sallem, Rafaella Iughetti da Costa, Lara Maria Fujita Vieira Lima, Micael Porto Portela Lima, Júlio César Claudino dos Santos, The role of medial prefrontal cortex in cognition, aging and Parkinson disease , Brazilian Journal of Clinical Medicine and Review: Vol. 1 No. 3 (2023): July/September - 2023
Ana Carolina Gomes de Oliveira, Isadora Vergamini Lamana, Natália Balbo Arantes Nogueira, Larissa Tarraf Bertazzo, Júlio César Claudino dos Santos, Luana Stangherlin, Attention-Deficit Hyperactivity Disorder (ADHD) and Sleep Disorders: What We Know Now and Where We are Headed , Brazilian Journal of Clinical Medicine and Review: Vol. 3 No. 1 (2025): January/December - 2025
Jacqueline Rodrigues Magalhães, Maria Madalena Correia Figueiredo, Ana Beatriz Teófilo Macedo dos Santos, Felipe Bergamasco Perri Cefali, Daniel de Oliveira Solfa, Rodolfo Basílio Madeira Neto, Sarah Gurgel Ponte Fontenelle, Marcelo Victor Fontenele Girão, Rafael Martin Barreiros, Luana Stangherlin, Júlio César Claudino dos Santos, The Relationship between Addictive Use of Social Media and Psychiatric Disorders: The Mediating Role of Emotion Dysregulation , Brazilian Journal of Clinical Medicine and Review: Vol. 2 No. 4 (2024): October/December - 2024
Maria Victória Rocha Fontenele Maia , Victor Hugo Melo Freitas, Lara Oliveira da Nóbrega , Lucas Olímpio Coimbra , Aline Moreira Lócio, Fairane Sousa Duarte, Rodrigo Mariano Ribeiro, Victor Monteiro Mororó, Sara Diógenes Peixoto de Medeiros , Amanda Rebouças Bezerra de Menezes , Rafaella Iughetti da Costa, Luciano Barroso de Albuquerque-Filho, Lara Maria Fujita Vieira Lima, Camilla Costa Sallem, Camilla Teixeira Pinheiro Gusmão, Yuri Borges Morais, Luiz da Silva Aldir, Tiago Antoniol, Isaac Dantas Sales Pimentel, Natalia Marinho Porto Lima , Júlio César Claudino dos Santos, Beyond behavioral changes in semantic dementia: principal hurdles on the road to the clinic , Brazilian Journal of Clinical Medicine and Review: Vol. 1 No. 3 (2023): July/September - 2023
Fernanda Susy Bessa Menezes Cavalcante, Laís Lobato de Araújo, Gabriel Felipe Gomes, Stéfani Lara Galvão, Talitta Costa Sant'ana Esteves Hipólito, Milene de Campos Piagentini, Júlio César Claudino dos Santos, Role of Gut-Microbiome-Brain-Axis in Neurodegenerative Diseases: A Review on Mechanisms and Potential Therapeutics , Brazilian Journal of Clinical Medicine and Review: Vol. 3 No. 1 (2025): January/December - 2025
Gabriel Felipe Gomes, Stéfani Lara Galvão, Caroline Ventura, Yasmin Paula Nobre Lessa, Júlio César Claudino dos Santos, The Role of Microglia in Parkinson's Disease and Possible Therapeutic Targets , Brazilian Journal of Clinical Medicine and Review: Vol. 3 No. 1 (2025): January/December - 2025
Victor Mendes Nóbrega Rocha, Vinicius Mendes Nóbrega Rocha, Gabriel Felipe Gomes, Stéfani Lara Galvão, Luiza Zatiti Monsanto de Paula, Maria Eduarda Osório de Oliveira, Isabela de Oliveira, Luiz Aldir da Silva, Victor Hugo Melo Freitas, Camilly Ramos Sales, Luana Stangherlin, Júlio César Claudino dos Santos, The role of Gut-Microbiome-Brain-axis in Alzheirmer's disease , Brazilian Journal of Clinical Medicine and Review: Vol. 2 No. 3 (2024): July/September - 2024
Flávio de Lima Filho, Giovana de Souza Faria, Artur Consulo Dionísio, Luana Passos Oliveira, Carolina Vieira Naia, Júlio César Claudino dos Santos, Prodromal Parkinson's Disease: What We Know and What We do Not Know , Brazilian Journal of Clinical Medicine and Review: Vol. 3 No. 1 (2025): January/December - 2025
Ana Carolina Westphal Guitti, Elba Virgínia Benítez Agüero, Helga Anna Loescher Abibe, Marina Maia Cavalcanti, Renata Reis Ligeiro, Bruno Cazarini de Moura, Regina Coeli de Carvalho Porto Carneiro, Mariana Silotti Cabelino Seyfarth, Marília Gersoni Bastos Reis Gomes, Gabriela Machado, Luana Stangherlin, Júlio César Claudino dos Santos, Renato Arruda, Marco Antônio Arruda, Marcelo Rodrigues Masruha, Autism Spectrum Disorder and Intellectual Disability: Where are We Now and What Challenges Lay Ahead? , Brazilian Journal of Clinical Medicine and Review: Vol. 3 No. 1 (2025): January/December - 2025
Isabela de Oliveira, Gabriel Felipe Gomes, Stéfani Lara Galvão, Victor Mendes Nóbrega Rocha, Vinicius Mendes Nóbrega Rocha, Camila Marciele Kammers, Júlio César Claudino dos Santos, Role of Gut-Brain Axis in Autism Spectrum Disorder: a Focus on the Neuroinflammation and Microglial Polarization , Brazilian Journal of Clinical Medicine and Review: Vol. 2 No. 4 (2024): October/December - 2024

1 2 > >>

[1] Zuzuárregui JRP, During EH. Sleep issues in Parkinson's disease and their management. Neurotherapeutics. 2020;17(4):1480–94. https://doi.org/10.1007/s13311-020-00938-y.

[2] Hunt J, Coulson EJ, Rajnarayanan R, Oster H, Videnovic A, Rawashdeh O. Sleep and circadian rhythms in Parkinson's disease and preclinical models. Mol Neurodegener. 2022;17(1):2. https://doi.org/10.1186/s13024-021-00504-w.

[3] Barone P, Antonini A, Colosimo C, Marconi R, Morgante L, Avarello TP, et al. The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. Mov Disord. 2009;24(11):1641–9. https://doi.org/10.1002/mds.22643.

[4] Ylikoski A, Martikainen K, Sieminski M, Partinen M. Parkinson's disease and insomnia. Neurol Sci. 2015;36(11):2003–10. https://doi.org/10.1007/s10072-015-2288-9.

[5] Erro R, Santangelo G, Picillo M, Vitale C, Amboni M, Longo K, et al. Link between non-motor symptoms and cognitive dysfunctions in de novo, drug-naive PD patients. J Neurol. 2012;259(9):1808–13. https://doi.org/10.1007/s00415-011-6407-0.

[6] Rosa-Grilo M, Qamar MA, Taddei RN, Pagonabarraga J, Kulisevsky J, Sauerbier A, et al. Rotigotine transdermal patch and sleep in Parkinson's disease: where are we now? NPJ Parkinsons Dis. 2017;3:28. https://doi.org/10.1038/s41531-017-0030-4.

[7] Tandberg E, Larsen JP, Karlsen K. A community-based study of sleep disorders in patients with Parkinson's disease. Mov Disord. 1998;13(6):895–9. https://doi.org/10.1002/mds.870130606.

[8] Trenkwalder C, Kohnen R, Högl B, Metta V, Sixel-Döring F, Frauscher B, et al. Parkinson's disease sleep scale--validation of the revised version PDSS-2. Mov Disord. 2011;26(4):644–52. https://doi.org/10.1002/mds.23476.

[9] Marinus J, Visser M, van Hilten JJ, Lammers GJ, Stiggelbout AM. Assessment of sleep and sleepiness in Parkinson disease. Sleep. 2003;26(8):1049–54. https://doi.org/10.1093/sleep/26.8.1049.

[10] Stavitsky K, Saurman JL, McNamara P, Cronin-Golomb A. Sleep in Parkinson's disease: a comparison of actigraphy and subjective measures. Parkinsonism Relat Disord. 2010;16(4):280–3. https://doi.org/10.1016/j.parkreldis.2010.02.001.

[11] Suzuki K, Miyamoto M, Miyamoto T, Okuma Y, Hattori N, Kamei S, et al. Correlation between depressive symptoms and nocturnal disturbances in Japanese patients with Parkinson's disease. Parkinsonism Relat Disord. 2009;15(1):15–9. https://doi.org/10.1016/j.parkreldis.2008.02.002.

[12] Gros P, Videnovic A. Sleep and circadian rhythm disorders in Parkinson's disease. Curr Sleep Med Rep. 2017;3(3):222–34. https://doi.org/10.1007/s40675-017-0079-y.

[13] Yoo SW, Kim JS, Oh YS, Ryu DW, Lee KS. Excessive daytime sleepiness and its impact on quality of life in de novo Parkinson's disease. Neurol Sci. 2019;40(6):1151–6. https://doi.org/10.1007/s10072-019-03785-8.

[14] Liguori C, Mercuri NB, Albanese M, Olivola E, Stefani A, Pierantozzi M. Daytime sleepiness may be an independent symptom unrelated to sleep quality in Parkinson's disease. J Neurol. 2019;266(3):636–41. https://doi.org/10.1007/s00415-018-09179-8.

[15] Frucht S, Rogers JD, Greene PE, Gordon MF, Fahn S. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology. 1999;52(9):1908–10. https://doi.org/10.1212/wnl.52.9.1908.

[16] Högl B, Seppi K, Brandauer E, Glatzl S, Frauscher B, Niedermüller U, et al. Increased daytime sleepiness in Parkinson's disease: a questionnaire survey. Mov Disord. 2003;18(3):319–23. https://doi.org/10.1002/mds.10365.

[17] Monaca C, Duhamel A, Jacquesson JM, Ozsancak C, Destée A, et al. Vigilance troubles in Parkinson's disease: a subjective and objective polysomnographic study. Sleep Med. 2006;7(5):448–53. https://doi.org/10.1016/j.sleep.2005.12.002.

[18] Amara AW, Chahine LM, Caspell-Garcia C, Long JD, Coffey C, Högl B, et al. Longitudinal assessment of excessive daytime sleepiness in early Parkinson's disease. J Neurol Neurosurg Psychiatry. 2017;88(8):653–62. https://doi.org/10.1136/jnnp-2016-315023.

[19] O'Suilleabhain PE, Dewey RB Jr. Contributions of dopaminergic drugs and disease severity to daytime sleepiness in Parkinson disease. Arch Neurol. 2002;59(6):986–9. https://doi.org/10.1001/archneur.59.6.986.

[20] Yeung EYH, Cavanna AE. Sleep attacks in patients with Parkinson's disease on dopaminergic medications: A systematic review. Mov Disord Clin Pract. 2014;1(4):307–16. https://doi.org/10.1002/mdc3.12063.

[21] Valko PO, Hauser S, Sommerauer M, Werth E, Baumann CR. Observations on sleep-disordered breathing in idiopathic Parkinson's disease. PLoS One. 2014;9(6). https://doi.org/10.1371/journal.pone.0100828.

[22] Kaminska M, Lafontaine AL, Kimoff RJ. The interaction between obstructive sleep apnea and Parkinson's disease: Possible mechanisms and implications for cognitive function. Parkinsons Dis. 2015;2015:849472. https://doi.org/10.1155/2015/849472.

[23] Neikrug AB, Liu L, Avanzino JA, Maglione JE, Natarajan L, Bradley L, et al. Continuous positive airway pressure improves sleep and daytime sleepiness in patients with Parkinson disease and sleep apnea. Sleep. 2014;37(1):177–85. https://doi.org/10.5665/sleep.3332.

[24] Kylstra WA, Aaronson JA, Hofman WF, Schmand BA. Neuropsychological functioning after CPAP treatment in obstructive sleep apnea: A meta-analysis. Sleep Med Rev. 2013;17(5):341–7. https://doi.org/10.1016/j.smrv.2012.09.002.

[25] Lévy P, Kohler M, McNicholas WT, Barbé F, McEvoy RD, Somers VK, et al. Obstructive sleep apnoea syndrome. Nat Rev Dis Primers. 2015;1:15015. https://doi.org/10.1038/nrdp.2015.15.

[26] Trotti LM, Bliwise DL. No increased risk of obstructive sleep apnea in Parkinson's disease. Mov Disord. 2010;25(13):2246–9. https://doi.org/10.1002/mds.23231.

[27] Cochen De Cock V, Abouda M, Leu S, Oudiette D, Roze E, Vidailhet M, et al. Is obstructive sleep apnea a problem in Parkinson's disease? Sleep Med. 2010;11(3):247–52. https://doi.org/10.1016/j.sleep.2009.05.008.

[28] Bahia CMCS, Pereira JS, Lopes AJ. Laryngopharyngeal motor dysfunction and obstructive sleep apnea in Parkinson's disease. Sleep Breath. 2019;23(2):543–50. https://doi.org/10.1007/s11325-018-1729-0.

[29] Tsai CC, Wu MN, Liou LM, Chang YP. Levodopa reverses stridor and prevents subsequent endotracheal intubation in Par-kinson disease patients with bilateral vocal cord palsy: A case report. Medicine (Baltimore). 2016;95(50). https://doi.org/10.1097/MD.0000000000005559.

[30] Mery VP, Gros P, Lafontaine AL, Robinson A, Benedetti A, Kimoff RJ, et al. Reduced cognitive function in patients with Parkinson disease and obstructive sleep apnea. Neurology. 2017;88(12):1120–8. https://doi.org/10.1212/WNL.0000000000003738.

[31] Huang JY, Zhang JR, Shen Y, Zhang HJ, Cao YL, Mao CJ, et al. Effect of rapid eye movement sleep behavior disorder on obstructive sleep apnea severity and cognition of Parkinson's disease patients. Chin Med J (Engl). 2018;131(8):899–906. https://doi.org/10.4103/0366-6999.229888.

[32] Arnulf I, Konofal E, Merino-Andreu M, Houeto JL, Mesnage V, Lacomblez L, et al. Parkinson's disease and sleepiness: An integral part of PD. Neurology. 2002;58(7):1019–24. https://doi.org/10.1212/wnl.58.7.1019.

[33] Hardie RJ, Efthimiou J, Stern GM. Respiration and sleep in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1986;49(11):1326. https://doi.org/10.1136/jnnp.49.11.1326.

[34] Hovestadt A, Bogaard JM, Meerwaldt JD, van der Meché FG, Stigt J. Pulmonary function in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1989;52(3):329–33. https://doi.org/10.1136/jnnp.52.3.329.

[35] Darien IL. The diagnostic criteria of the American Academy of Sleep Medicine. The International Classification of Sleep Disorders. 3rd ed. Darien (IL): American Academy of Sleep Medicine; 2014.

[36] Bonuccelli U, Del Dotto P, Lucetti C, Petrozzi L, Bernardini S, Gambaccini G, et al. Diurnal motor variations to repeated doses of levodopa in Parkinson's disease. Clin Neuropharmacol. 2000;23(1):28–33. https://doi.org/10.1097/00002826-200001000-00006.

[37] Bolitho SJ, Naismith SL, Rajaratnam SM, Grunstein RR, Hodges JR, Terpening Z, et al. Disturbances in melatonin secretion and circadian sleep-wake regulation in Parkinson disease. Sleep Med. 2014;15(3):342–7. https://doi.org/10.1016/j.sleep.2013.10.016.

[38] Golombek DA, Rosenstein RE. Physiology of circadian entrainment. Physiol Rev. 2010;90(3):1063–102. https://doi.org/10.1152/physrev.00009.2009.

[39] Breen DP, Vuono R, Nawarathna U, Fisher K, Shneerson JM, Reddy AB, et al. Sleep and circadian rhythm regulation in early Parkinson disease. JAMA Neurol. 2014;71(5):589–95. https://doi.org/10.1001/jamaneurol.2014.65.

[40] Paus S, Schmitz-Hübsch T, Wüllner U, Vogel A, Klockgether T, Abele M. Bright light therapy in Parkinson's disease: A pilot study. Mov Disord. 2007;22(10):1495–8. https://doi.org/10.1002/mds.21542.

[41] Videnovic A, Klerman EB, Wang W, Marconi A, Kuhta T, Zee PC. Timed light therapy for sleep and daytime sleepiness associated with Parkinson disease: A randomized clinical trial. JAMA Neurol. 2017;74(4):411–8. https://doi.org/10.1001/jamaneurol.2016.5192.

[42] Willis GL, Turner EJ. Primary and secondary features of Parkinson's disease improve with strategic exposure to bright light: A case series study. Chronobiol Int. 2007;24(3):521–37. https://doi.org/10.1080/07420520701420717.

[43] Zhong G, Bolitho S, Grunstein R, Naismith SL, Lewis SJ. The relationship between thermoregulation and REM sleep behaviour disorder in Parkinson's disease. PLoS One. 2013;8(8). https://doi.org/10.1371/journal.pone.0072661.

[44] Bordet R, Devos D, Brique S, Touitou Y, Guieu JD, Libersa C, et al. Study of circadian melatonin secretion pattern at different stages of Parkinson's disease. Clin Neuropharmacol. 2003;26(2):65–72. https://doi.org/10.1097/00002826-200303000-00005.

[45] Cai Y, Liu S, Sothern RB, Xu S, Chan P. Expression of clock genes Per1 and Bmal1 in total leukocytes in health and Parkinson's disease. Eur J Neurol. 2010;17(4):550–4. https://doi.org/10.1111/j.1468-1331.2009.02848.x.

[46] Mantovani S, Smith SS, Gordon R, O'Sullivan JD. An overview of sleep and circadian dysfunction in Parkinson's disease. J Sleep Res. 2018;27(3). https://doi.org/10.1111/jsr.12673.

[47] Garcia-Borreguero D, Serrano C, Larrosa O, Granizo JJ. Circadian effects of dopaminergic treatment in restless legs syndrome. Sleep Med. 2004;5(4):413–20. https://doi.org/10.1016/j.sleep.2004.01.007.

[48] Verbaan D, van Rooden SM, van Hilten JJ, Rijsman RM. Prevalence and clinical profile of restless legs syndrome in Parkinson's disease. Mov Disord. 2010;25(13):2142–7. https://doi.org/10.1002/mds.23241.

[49] Yang X, Liu B, Shen H, Li S, Zhao Q, An R, et al. Prevalence of restless legs syndrome in Parkinson's disease: A systematic review and meta-analysis of observational studies. Sleep Med. 2018;43:40–6. https://doi.org/10.1016/j.sleep.2017.11.1146.

[50] Szatmari S Jr, Bereczki D, Fornadi K, Kalantar-Zadeh K, Kovesdy CP, Molnar MZ. Association of restless legs syndrome with incident Parkinson's disease. Sleep. 2017;40(2). https://doi.org/10.1093/sleep/zsw065.

[51] Lee JE, Shin HW, Kim KS, Sohn YH. Factors contributing to the development of restless legs syndrome in patients with Parkinson disease. Mov Disord. 2009;24(4):579–82. https://doi.org/10.1002/mds.22410.

[52] Angelini M, Negrotti A, Marchesi E, Bonavina G, Calzetti S. A study of the prevalence of restless legs syndrome in previously untreated Parkinson's disease patients: Absence of co-morbid association. J Neurol Sci. 2011;310(1-2):286–8. https://doi.org/10.1016/j.jns.2011.08.012.

[53] Moccia M, Erro R, Picillo M, Santangelo G, Spina E, Allocca R, et al. A four-year longitudinal study on restless legs syndrome in Parkinson disease. Sleep. 2016;39(2):405–12. https://doi.org/10.5665/sleep.5452.

[54] Ferini-Strambi L, Carli G, Casoni F, Galbiati A. Restless legs syndrome and Parkinson disease: A causal relationship between the two disorders? Front Neurol. 2018;9:551. https://doi.org/10.3389/fneur.2018.00551.

[55] Alonso-Navarro H, García-Martín E, Agúndez JAG, Jiménez-Jiménez FJ. Association between restless legs syndrome and other movement disorders. Neurology. 2019;92(20):948–64. https://doi.org/10.1212/WNL.0000000000007500.

[56] Allen RP, Picchietti DL, Garcia-Borreguero D, Ondo WG, Walters AS, Winkelman JW, et al. Restless legs syndro-me/Willis-Ekbom disease diagnostic criteria: Updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria—history, rationale, description, and significance. Sleep Med. 2014;15(8):860–73. https://doi.org/10.1016/j.sleep.2014.03.025.

[57] Silber MH, Becker PM, Earley C, Garcia-Borreguero D, Ondo WG, Medical Advisory Board of the Willis-Ekbom Disease Foundation. Willis-Ekbom Disease Foundation revised consensus statement on the management of restless legs syndrome. Mayo Clin Proc. 2013;88(9):977–86. https://doi.org/10.1016/j.mayocp.2013.06.016.

[58] Ondo WG. Common comorbidities and differential diagnosis of restless legs syndrome. J Clin Psychiatry. 2014;75(3). https://doi.org/10.4088/JCP.12074nr2c.

[59] Garcia-Borreguero D, Kohnen R, Silber MH, Winkelman JW, Earley CJ, Högl B, et al. The long-term treatment of restless legs syndrome/Willis-Ekbom disease: Evidence-based guidelines and clinical consensus best practice guidance: A report from the International Restless Legs Syndrome Study Group. Sleep Med. 2013;14(7):675–84. https://doi.org/10.1016/j.sleep.2013.05.016.

[60] Cochen De Cock V. Therapies for restless legs in Parkinson's disease. Curr Treat Options Neurol. 2019;21(11):56. https://doi.org/10.1007/s11940-019-0596-8.

[61] Maria B, Sophia S, Michalis M, Charalampos L, Andreas P, John ME, et al. Sleep breathing disorders in patients with idiopathic Parkinson's disease. Respir Med. 2003;97(10):1151–7. https://doi.org/10.1016/s0954-6111(03)00188-4.

[62] Schroeder LA, Rufra O, Sauvageot N, Fays F, Pieri V, Diederich NJ. Reduced rapid eye movement density in Parkinson disease: A polysomnography-based case-control study. Sleep. 2016;39(12):2133–9. https://doi.org/10.5665/sleep.6312.

[63] Diederich NJ, Rufra O, Pieri V, Hipp G, Vaillant M. Lack of polysomnographic Non-REM sleep changes in early Parkinson's disease. Mov Disord. 2013;28(10):1443–6. https://doi.org/10.1002/mds.25520.

[64] Wetter TC, Brunner H, Högl B, Yassouridis A, Trenkwalder C, Friess E. Increased alpha activity in REM sleep in de novo patients with Parkinson's disease. Mov Disord. 2001;16(5):928–33. https://doi.org/10.1002/mds.1163.

[65] Margis R, Schönwald SV, Carvalho DZ, Gerhardt GJ, Rieder CR. NREM sleep alpha and sigma activity in Parkinson's disease: Evidence for conflicting electrophysiological activity? Clin Neurophysiol. 2015;126(5):951–8. https://doi.org/10.1016/j.clinph. 2014.07.034.

[66] Ohayon MM, Schenck CH. Violent behavior during sleep: Prevalence, comorbidity and consequences. Sleep Med. 2010;11(9):941–6. https://doi.org/10.1016/j.sleep.2010.02.016.

[67] Högl B, Stefani A, Videnovic A. Idiopathic REM sleep behaviour disorder and neurodegeneration—An update. Nat Rev Neurol. 2018;14(1):40–55. https://doi.org/10.1038/nrneurol.2017.157.

[68] Iranzo A, Tolosa E, Gelpi E, Molinuevo JL, Valldeoriola F, Serradell M, et al. Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: An observational cohort study. Lancet Neurol. 2013;12(5):443–53. https://doi.org/10.1016/S1474-4422(13)70056-5.

[69] Boeve BF, Silber MH, Ferman TJ, Lin SC, Benarroch EE, Schmeichel AM, et al. Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder. Sleep Med. 2013;14(8):754–62. https://doi.org/10.1016/j.sleep.2012.10.015.

[70] Mahlknecht P, Seppi K, Poewe W. The concept of prodromal Parkinson's disease. J Parkinsons Dis. 2015;5(4):681–97. https://doi.org/10.3233/JPD-150685.

[71] Pagano G, De Micco R, Yousaf T, Wilson H, Chandra A, Politis M. REM behavior disorder predicts motor progression and cognitive decline in Parkinson disease. Neurology. 2018;91(10)–e905. https://doi.org/10.1212/WNL.0000000000006134.

[72] Oertel WH, Henrich MT, Janzen A, Geibl FF. The locus coeruleus: Another vulnerability target in Parkinson's disease. Mov Disord. 2019;34(10):1423–9. https://doi.org/10.1002/mds.27785.

[73] Weinshenker D. Long road to ruin: Noradrenergic dysfunction in neurodegenerative disease. Trends Neurosci. 2018;41(4):211–23. https://doi.org/10.1016/j.tins.2018.01.010.

[74] Gjerstad MD, Tysnes OB, Larsen JP. Increased risk of leg motor restlessness but not RLS in early Parkinson disease. Neurology. 2011;77(22):1941–6. https://doi.org/10.1212/WNL.0b013e31823a0cc8.

[75] Pierantozzi M, Placidi F, Liguori C, Albanese M, Imbriani P, Marciani MG, et al. Rotigotine may improve sleep architecture in Parkinson's disease: A double-blind, randomized, placebo-controlled polysomnographic study. Sleep Med. 2016;21:140–4. https://doi.org/10.1016/j.sleep.2016.01.016.

[76] Seppi K, Ray Chaudhuri K, Coelho M, Fox SH, Katzenschlager R, Perez Lloret S, et al. Update on treatments for nonmotor symptoms of Parkinson's disease—an evidence-based medicine review. Mov Disord. 2019;34(2):180–98. https://doi.org/10.1002/mds.27602.

[77] Postuma RB, Anang J, Pelletier A, Joseph L, Moscovich M, Grimes D, et al. Caffeine as symptomatic treatment for Parkinson disease (Café-PD): A randomized trial. Neurology. 2017;89(17):1795–803. https://doi.org/10.1212/WNL.0000000000004568.

[78] Winkelman JW, Armstrong MJ, Allen RP, Chaudhuri KR, Ondo W, Trenkwalder C, et al. Practice guideline summary: Tre-atment of restless legs syndrome in adults: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2016;87(24):2585–93. https://doi.org/10.1212/WNL.00000000 00003388.

[79] Allen RP, Picchietti DL, Garcia-Borreguero D, Ondo WG, Walters AS, Winkelman JW, et al. Restless legs syndro-me/Willis-Ekbom disease diagnostic criteria: Updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria—history, rationale, description, and significance. Sleep Med. 2014;15(8):860–73. https://doi.org/10.1016/j.sleep.2014.03.025.

[80] Howell MJ, Arneson PA, Schenck CH. A novel therapy for REM sleep behavior disorder (RBD). J Clin Sleep Med. 2011;7(6):639–44A. https://doi.org/10.5664/jcsm.1470.

[81] Wang Y, Yang Y, Wu H, Lan D, Chen Y, Zhao Z. Effects of Rotigotine on REM Sleep Behavior Disorder in Parkinson Disease. J Clin Sleep Med. 2016;12(10):1403–9. https://doi.org/10.5664/jcsm.6200.

[82] Di Giacopo R, Fasano A, Quaranta D, Della Marca G, Bove F, Bentivoglio AR. Rivastigmine as alternative treatment for refractory REM behavior disorder in Parkinson's disease. Mov Disord. 2012;27(4):559–61. https://doi.org/10.1002/mds.24909.

[83] Schenck CH, Högl B, Videnovic A, eds. Rapid-eye-movement sleep behavior disorder. Cham: Springer; 2019.

[84] Stefani A, Högl B. Sleep in Parkinson’s disease. Neuropsychopharmacol Rep. 2020;40(5):362–70. https://doi.org/10.1002/ npr2.12152.

[85] Pierantozzi M, Placidi F, Liguori C, Albanese M, Imbriani P, Marciani MG, et al. Rotigotine may improve sleep architecture in Parkinson's disease: A double-blind, randomized, placebo-controlled polysomnographic study. Sleep Med. 2016;21:140–4. https://doi.org/10.1016/j.sleep.2016.01.016.

[86] Seppi K, Ray Chaudhuri K, Coelho M, Fox SH, Katzenschlager R, Perez Lloret S, et al. Update on treatments for nonmotor symptoms of Parkinson's disease—an evidence-based medicine review. Mov Disord. 2019;34(2):180–98. https://doi.org/ 10.1002/mds.27602.

[87] Neikrug AB, Liu L, Avanzino JA, Maglione JE, Natarajan L, Bradley L, et al. Continuous positive airway pressure improves sleep and daytime sleepiness in patients with Parkinson disease and sleep apnea. Sleep. 2014;37(1):177–85. https://doi.org/10.5665/sleep.3332.

[88] Schäfer D. Schlafbezogene Atmungsstörungen bei Parkinsonsyndromen: Häufigkeit, Art und Behandlungsansätze: Sleep-related breathing disorders in Parkinsonism: Frequency, nature, and therapeutical approaches. Somnologie. 2001;5(3):103–14.

[89] Bollu PC, Sahota P. Sleep and Parkinson Disease. Mo Med. 2017;114(5):381–6.

[90] Videnovic A, Klerman EB, Wang W, Marconi A, Kuhta T, Zee PC. Timed light therapy for sleep and daytime sleepiness associated with Parkinson disease: A randomized clinical trial. JAMA Neurol. 2017;74(4):411–8. https://doi.org/10.1001/jamaneurol.2016.5192.

[91] Wang Y, Yang Y, Wu H, Lan D, Chen Y, Zhao Z. Effects of Rotigotine on REM sleep behavior disorder in Parkinson disease. J Clin Sleep Med. 2016;12(10):1403–9. https://doi.org/10.5664/jcsm.6200.

[92] Di Giacopo R, Fasano A, Quaranta D, Della Marca G, Bove F, Bentivoglio AR. Rivastigmine as alternative treatment for refractory REM behavior disorder in Parkinson's disease. Mov Disord. 2012;27(4):559–61. https://doi.org/10.1002/mds.24909.

[93] Howell MJ, Arneson PA, Schenck CH. A novel therapy for REM sleep behavior disorder (RBD). J Clin Sleep Med. 2011;7(6):639–44A. https://doi.org/10.5664/jcsm.1470.

[94] Allen RP, Picchietti DL, Garcia-Borreguero D, Ondo WG, Walters AS, Winkelman JW, et al. Restless legs syndro-me/Willis-Ekbom disease diagnostic criteria: Updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria—history, rationale, description, and significance. Sleep Med. 2014;15(8):860–73. https://doi.org/10.1016/j.sleep.2014.03.025.

[95] Silber MH, Becker PM, Earley C, Garcia-Borreguero D, Ondo WG, Medical Advisory Board of the Willis-Ekbom Disease Foundation. Willis-Ekbom Disease Foundation revised consensus statement on the management of restless legs syndrome. Mayo Clin Proc. 2013;88(9):977–86. https://doi.org/10.1016/j.mayocp.2013.06.016.

[96] Ondo WG. Common comorbidities and differential diagnosis of restless legs syndrome. J Clin Psychiatry. 2014;75(3). https://doi.org/10.4088/JCP.12074nr2c.

[97] Garcia-Borreguero D, Kohnen R, Silber MH, Winkelman JW, Earley CJ, Högl B, et al. The long-term treatment of restless legs syndrome/Willis-Ekbom disease: Evidence-based guidelines and clinical consensus best practice guidance: A report from the International Restless Legs Syndrome Study Group. Sleep Med. 2013;14(7):675–84. https://doi.org/10.1016/j.sleep.2013.05.016.

[98] Cochen De Cock V. Therapies for restless legs in Parkinson's disease. Curr Treat Options Neurol. 2019;21(11):56. https://doi.org/10.1007/s11940-019-0596-8.

[99] Schenck CH, Högl B, Videnovic A, editors. Rapid-eye-movement sleep behavior disorder. Cham: Springer; 2019.

[100] Wang Y, Yang Y, Wu H, Lan D, Chen Y, Zhao Z. Effects of Rotigotine on REM sleep behavior disorder in Parkinson disease. J Clin Sleep Med. 2016;12(10):1403–9. https://doi.org/10.5664/jcsm.6200.

[101] Di Giacopo R, Fasano A, Quaranta D, Della Marca G, Bove F, Bentivoglio AR. Rivastigmine as alternative treatment for refractory REM behavior disorder in Parkinson's disease. Mov Disord. 2012;27(4):559–61. https://doi.org/10.1002/mds.24909.

[102] Stefani A, Högl B, Videnovic A. Non-motor features of Parkinson's disease and sleep disorders: Practical guidelines for assessment and management. Mov Disord Clin Pract. 2020;7(3):250–66. https://doi.org/10.1002/mdc3.12899.

[103] Pierantozzi M, Placidi F, Liguori C, Albanese M, Imbriani P, Marciani MG, et al. Rotigotine may improve sleep architecture in Parkinson's disease: A double-blind, randomized, placebo-controlled polysomnographic study. Sleep Med. 2016;21:140–4. https://doi.org/10.1016/j.sleep.2016.01.016.

[104] Seppi K, Ray Chaudhuri K, Coelho M, Fox SH, Katzenschlager R, Perez Lloret S, et al. Update on treatments for nonmotor symptoms of Parkinson's disease—An evidence-based medicine review. Mov Disord. 2019;34(2):180–98. https://doi.org/10.1002/mds.27602.

[105] Postuma RB, Anang J, Pelletier A, Joseph L, Moscovich M, Grimes D, et al. Caffeine as symptomatic treatment for Parkinson disease (Café-PD): A randomized trial. Neurology. 2017;89(17):1795–803. https://doi.org/10.1212/WNL.0000000000004568.

[106] Neikrug AB, Liu L, Avanzino JA, Maglione JE, Natarajan L, Bradley L, et al. Continuous positive airway pressure improves sleep and daytime sleepiness in patients with Parkinson disease and sleep apnea. Sleep. 2014;37(1):177–85. https://doi.org/10.5665/sleep.3332.

[107] Schäfer D. Schlafbezogene Atmungsstörungen bei Parkinsonsyndromen: Häufigkeit, Art und Behandlungsansätze: Sleep-related breathing disorders in Parkinsonism: Frequency, nature, and therapeutical approaches. Somnologie. 2001;5(3):103–14. https://doi.org/10.1007/s11818-001-0015-5.

[108] Winkelman JW, Armstrong MJ, Allen RP, Chaudhuri KR, Ondo W, Trenkwalder C, et al. Practice guideline summary: Tre-atment of restless legs syndrome in adults: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2016;87(24):2585–93. https://doi.org/10.1212/WNL.00000000 00003388.

[109] Videnovic A, Klerman EB, Wang W, Marconi A, Kuhta T, Zee PC. Timed light therapy for sleep and daytime sleepiness associated with Parkinson disease: A randomized clinical trial. JAMA Neurol. 2017;74(4):411–8. https://doi.org/10.1001/jamaneurol.2016.5192.

[110] Paus S, Schmitz-Hübsch T, Wüllner U, Vogel A, Klockgether T, Abele M. Bright light therapy in Parkinson's disease: A pilot study. Mov Disord. 2007;22(10):1495–8. https://doi.org/10.1002/mds.21542.

[111] Howell MJ, Arneson PA, Schenck CH. A novel therapy for REM sleep behavior disorder (RBD). J Clin Sleep Med. 2011;7(6):639–44A. https://doi.org/10.5664/jcsm.1470.

[112] Wang Y, Yang Y, Wu H, Lan D, Chen Y, Zhao Z. Effects of Rotigotine on REM sleep behavior disorder in Parkinson disease. J Clin Sleep Med. 2016;12(10):1403–9. https://doi.org/10.5664/jcsm.6200.

[113] Di Giacopo R, Fasano A, Quaranta D, Della Marca G, Bove F, Bentivoglio AR. Rivastigmine as alternative treatment for refractory REM behavior disorder in Parkinson's disease. Mov Disord. 2012;27(4):559–61. https://doi.org/10.1002/mds.24909.